Article
Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung.
British journal of biomedical science - 1 Oct 2017
Mohamad N, Jayalakshmi P, Rhodes A, Liam C-K, Tan J-L, Yousoof S, Rajadurai P
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death. Approximately 2-16% of NSCLC patients with wild-type epidermal growth factor receptor (EGFR) harbour anaplastic lymphoma kinase (ALK) mutations. Both EGFR and ALK mutations occur most commonly in Asian patients with NSCLC. As targeted therapy is available for NSCLC patients with these mutations, it is important to establish...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.